Přehled o publikaci
2024
Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
SZÁRAZ, Dávid; Vojtěch PEŘINA; Jana TREGLEROVÁ; Ctirad MACHÁČEK; Ondřej ZENDULKA et al.Basic information
Original name
Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
Authors
SZÁRAZ, Dávid; Vojtěch PEŘINA; Jana TREGLEROVÁ; Ctirad MACHÁČEK; Ondřej ZENDULKA and Petra BOŘILOVÁ LINHARTOVÁ
Edition
FRONTIERS IN ORAL HEALTH, LAUSANNE, FRONTIERS MEDIA SA, 2024, 2673-4842
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
Switzerland
Confidentiality degree
is not subject to a state or trade secret
References:
Marked to be transferred to RIV
Yes
RIV identification code
RIV/00216224:14110/24:00138460
Organization
Lékařská fakulta – Repository – Repository
UT WoS
EID Scopus
Keywords in English
osteonecrosis of the jaw; denosumab; statin; bisphosphonates; osteoporosis; MRONJ; case report; single dose
Links
EH22_008/0004644, research and development project. MUNI/A/1607/2023, interní kód Repo. 857560, interní kód Repo. RECETOX RI II, large research infrastructures.
Changed: 31/7/2025 00:50, RNDr. Daniel Jakubík
Abstract
In the original language
Both denosumab (DMB) and bisphosphonates (BPs), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ). Besides ARDs, statins were recently associated with MRONJ development, especially in patients taking higher doses of statins for a longer period of time. Here, we report a case of a female patient with osteoporosis using statins and treated with alendronate for 3 years who rapidly developed MRONJ stage III after only a single low dose of DMB. After partial maxillectomy complete healing was observed without any recurrence. We performed a literature review of cases with MRONJ triggered by a single low dose of DMB, with or without previous application of other ARDs. Only six similar cases of patients who developed MRONJ after a single low dose of DMB following previous BP therapy have been reported so far. Besides these, literature reports one patient who developed MRONJ after a single dose of DMB following romosozumab treatment and five cases developing MRONJ after a single dose of DMB even without any previous ARD treatment. We suggest that before DMB therapy is initiated, all factors predisposing to MRONJ development should be considered.
